GlassScriptPhysician profile
Bridget J Smith
NPI 1205982105
$4,165.40
in general payments reported to CMS, 2019-2025
19 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $228 · 2023: $882 · 2024: $1,393 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,538.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $630.24 | 2024-2025 | Watchman Flx, Bodyguardian, General - Therapies |
| Astrazeneca Pharmaceuticals LP | $611.66 | 2021-2023 | Farxiga |
| Abbott Laboratories | $574.95 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Aveir |
| Pfizer INC. | $431.39 | 2021-2025 | |
| Abiomed | $264.91 | 2023-2025 | Impella |
| Kestra Medical Technology Services, INC. | $195.97 | 2025 | Assure Wcd |
| Glaxosmithkline, LLC. | $182.21 | 2025 | |
| Cvrx, INC. | $142.22 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.85 | 2024-2025 | Lifevest |
| Edwards Lifesciences Corporation | $131.19 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Neurocrine Biosciences, INC. | $126.45 | 2024 | Ingrezza |
| Alnylam Pharmaceuticals INC. | $125.00 | 2024 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $120.39 | 2023 | Rexulti |
| Sage Therapeutics, LLC | $112.62 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $105.63 | 2024 | Dojolvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $95.00 | 2021 | |
| Biotronik INC. | $87.67 | 2024-2025 | Biomonitor, Amvia Edge |
| Masimo Corporation | $67.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.